Biogen Inc. (BIIB) Earnings Call Transcript & Summary

July 31, 2025

NASDAQ US Health Care Biotechnology earnings 64 min

Earnings Call Speaker Segments

Tim Power

executive
#1

Cynthia, thank you — and a good morning to all of you. It's a pleasure to have you join us for Biogen's earnings call covering the second quarter of 2025. We will be sharing forward-looking statements on this call, and those carry risks and uncertainties that could lead actual results to differ materially from what those forward-looking statements suggest. In our SEC filings, we offer a comprehensive list of risk factors, and I'd encourage you to take a look at it. You can find our earnings release and the other documents related to our results, along with reconciliations between GAAP and non-GAAP results discussed on this call, on the investors section of biogen.com. The slides we'll be using during the call have also been posted to our website. Joining me today are our President and Chief Executive Officer, Christopher Viehbacher, Dr. Priya Singhal, Head of Development, Alisha Alaimo, our President and Head of North America, and Robin Kramer, our Chief Financial Officer; we'll offer some opening comments and then move to Q&A. So that we can get through as many questions as possible, we kindly ask that you limit yourself to just one question. I'll now turn the call over to Chris.

Christopher Viehbacher

executive
#2

Thanks, Tim, and good morning, everybody. We're quite pleased with the way the second quarter unfolded. More precisely, gains from recently introduced products have been making up for the decline in MS. On top of that, MS proved a bit more durable over the course of this quarter. We did see some gross-to-net adjustment, though I'd like to call attention to how VUMERITY did. In my view, Alisha and her U.S. team have devoted a great deal of effort to VUMERITY over the last two years, and the expansion we're observing is pretty encouraging; this product still has substantial market exclusivity remaining. Turning to the growth products, it also looks like LEQEMBI keeps expanding at a steady pace. There are a number of things coming along that we hope will relieve some of the pressure points in the system. Among them are blood-based biomarkers — the first has already received approval, and today there are several biomarker tests on the market. We also have a PDUFA date at the end of August for our subcutaneous maintenance formulation. My sense is that these developments are beginning to generate a possible change in trajectory for LEQEMBI, though Alisha will go into more detail on that. Overall, we're feeling pretty positive about the signs we're seeing. Turning to SKYCLARYS, it's now on the market in 29 countries. Our patient count outside the U.S. is probably equal to or even greater than what we have domestically, and the launch is going very smoothly. Reimbursement isn't in place for every patient just yet. As we move through each market, we've managed to enroll quite a few people into early access programs. The uptake within those programs has been remarkably strong, and from there we tackle reimbursement on a market-by-market basis. ZURZUVAE delivered a really solid quarter. Alisha can probably add further detail, though in my view it's something of an underappreciated asset within our portfolio. It is clearly doing better than what we had projected internally. There was also encouraging news during the quarter: European approval came through, and we're eager to begin mapping out the launch in that region. Regarding what's coming up in our development queue, Priya will certainly have additional details to share, though there's encouraging progress to report. Every phase III trial involving felzartamab is now underway, and there's a possibility of launching one more study focused on microvascular inflammation, which would expand that collection of programs. Results from salanersen came back looking genuinely compelling. That represents our follow-on offering for SMA, and enthusiasm around it is high—it will be an additional phase III kicking off during this year. On the business development side, we keep evaluating opportunities throughout the entire range of what's in our development pipeline. The research agreement we finalized last quarter with City Therapeutics has us quite enthusiastic, and I'd anticipate a number of additional research collaborations of that kind during this year. We keep evaluating later-stage opportunities, in terms of both M&A and collaborations. Again, we remain disciplined in ensuring that anything we take on would deliver value to shareholders. Turning to the quarter, I'd characterize our performance as growth on the top line as well as the bottom line. Our approach to cost control has been extremely strict, and from where I sit the company is performing nicely; that said, I'll now pass it to Priya, who is in a position to take us through far more detail on the pipeline.

Priya Singhal

executive
#3

Thanks, Chris. During this quarter, we achieved meaningful strides as we kept expanding both the scope and the depth of our pipeline in important areas. In Europe, we received a favorable CHMP opinion for ZURZUVAE. We kicked off three phase III trials: a pediatric phase III study of SKYCLARYS, plus felzartamab phase III trials for IgAN and PMN. Together with Stoke Therapeutics, we are moving toward an imminent FPI for salanersen. In addition, we are pursuing expansion of felzartamab into a fourth indication known as late microvascular inflammation, or MVI, in individuals who have undergone a kidney transplant; backing our ongoing scientific leadership, we also shared fresh data spanning our main franchises at medical congresses, among them Cure SMA, EPNS, EULAR, and LUPUS 2025. Only yesterday, at AAIC, new long-term findings on LEQEMBI were presented, showing treatment benefits across four years of continued use, along with bioequivalence data for the initiation dose of subcutaneous lecanemab. During this quarter, we also reported promising new interim phase 1b results for salanersen in SMA, as Chris noted, which demonstrate proof of concept. As the company that drove the transformation in SMA, we are thrilled by the possibility of carrying that journey forward and potentially tackling the residual unmet needs that patients still face. Salanersen works through the very same mechanism of action as SPINRAZA, yet it was engineered as a more potent molecule, thereby opening the potential for high efficacy with dosing just once each year — a profile we think can further serve the needs of the SMA community. The phase 1b study enrolled children who had already received gene therapy but who had not reached the motor milestones expected for their age, such as sitting, standing, or walking, even though a lengthy period had passed since they got the gene therapy. Last month, at the Cure SMA meeting, we presented the interim results from this study. Next, I'd like to walk you through the key features of those data. Although the data set is small, a number of features stand out. First, salanersen was assessed with administration once a year. Second, we are observing a substantial drop in neurofilament, which, as you are aware, serves as a marker of neurodegeneration. Third, we saw meaningful gains in motor function, including the reaching of significant motor milestones; on the right-hand side of this slide, two examples appear of participants who had previously been given gene therapy several years before they received salanersen. The first row shows a child who got gene therapy at roughly one year of age and was unable to sit when they entered this trial at about five years of age. That child received one dose of salanersen 80 milligrams, and by the 90-day visit, they could sit independently. Of course, these results must be confirmed in a registrational trial. Data like these support salanersen's potential to transform the standard of care in SMA, and we are acting with urgency as we engage global regulators and finalize the phase III study design. Now, on our lupus programs, we and UCB were thrilled to share fresh results from the successful phase III trial of daprolizumab in SLE. Patients tell us that fatigue shows up extremely often in lupus. As many as 90% of those with the condition deal with it, and it's frequently called the symptom that disables them most. It may appear as an intense, unrelenting, and exhausting weariness, and treating it in lupus has shown itself to be quite hard. The key point regarding this updated analysis we shared at EULAR is that daprolizumab produced steady gains across several areas of fatigue over and above what standard of care by itself could deliver. That covers the recently created FATIGUE-PRO, a new way of measuring fatigue among SLE patients. These findings strengthen even more the possibility that daprolizumab can tackle the outstanding need and turn into a significant novel therapy for SLE. Looking back at what we accomplished in this quarter, I think we are advancing reliably toward our aim of overhauling the pipeline and bringing the new Biogen to life. Over the coming 12 to 18 months, a number of major anticipated scientific milestones and regulatory decisions lie ahead, among them LEQEMBI subcutaneous maintenance along with high-dose SPINRAZA. Because the pipeline sits at the heart of our long-term growth plan, we intend to follow up last quarter's felzartamab investor webcast by holding a second thematic seminar in the fall, this time centered on our lupus pipeline. With that said, I'd like to pass the call to Alisha now for an update on our commercial business. Thank you.

Alisha Alaimo

executive
#4

Thanks, Priya, and good morning to all of you. In my remarks today, I want to walk through the solid commercial performance we posted in Q2, and also explain how shifting market conditions opened up fresh opportunities that fueled our latest growth. You may recall that over 18 months back, through our Fit for Growth initiative, we moved capital around to get ready for four launches in the U.S. market. We scrutinized where our MS investments generate the best returns, and as of today, we feel those choices are paying off. Before I get into the launch products, I want to note that our MS business continues to be resilient and a meaningful source of cash flow. Turning to Q2 results, beyond certain one-time items that helped the quarter, I'm pleased with how VUMERITY performed as it kept expanding; in our view, this shows the worth of our team's deep institutional knowledge, solid access, and immunology relationships. Now to SKYCLARYS: we are fulfilling our pledge to deliver the first Friedreich's Ataxia therapy to patients worldwide. SKYCLARYS has reached 29 markets around the globe, among them major European nations and Brazil. Moving into additional markets helps us unlock SKYCLARYS's full potential, and revenue rose 5% worldwide versus the prior quarter. At this point last year, I described the intentional pivot our U.S. rare disease team made, shifting investment toward reaching the remaining patients treated in the community rather than our original patients, who were mostly at centers of excellence; we found that community patients had a distinct profile. Typically they are older, on average beyond 40 years of age, and frequently have slower progressing forms of FA; bear in mind that community neurologists and primary care providers might see just one or two FA patients over an entire career, so extra education can be needed. We've brought advanced rare disease capabilities to bear on finding patients in need and assisting HCPs in grasping the progressive nature of the disease and the possible urgency of beginning treatment on SKYCLARYS. In my view, this change in focus was a major driver of the 13% quarter-over-quarter revenue increase in the U.S. During Q2, roughly 70% of new start forms came from community neurologists and PCPs. That strengthens our confidence in our capacity to reach the remaining patient population in need. As we've said previously, although we expect continued U.S. growth, the pace could vary quarter-to-quarter given how long it can take to find and reach potential patients; we stay optimistic about the worldwide opportunity and were heartened that new clinical guidelines from the top patient advocacy group and KMEs globally recommend intervention with SKYCLARYS; in our view, this is building momentum and prescriber awareness for the sole DMT that slows Friedreich's Ataxia progression. Moving on now to ZURZUVAE. In the U.S., revenue rose 68% versus the prior quarter, and new prescribers were up 29%. We grew our field team earlier in the year, and within only a few months, the results they are producing strengthen our confidence that ZURZUVAE can grow steadily over time. Nearly 70% of scripts now come from repeat prescribers, which we see as a sign that HCPs increasingly trust ZURZUVAE and are willing to use it for PPD. During the last quarter, 80% of ZURZUVAE prescriptions were written for first-line therapy. At present, most reimbursement policies call for neither step edits nor complicated prior authorizations, which helps speed up patient access. Going forward, we hope to make ZURZUVAE available to patients beyond the United States. Finally, turning to LEQEMBI, a major evolution is under way in the U.S. Alzheimer's market, one that started when LEQEMBI received FDA approval only two years ago. To speed up this large-scale change, our launch efforts centered mainly on assisting health systems in building the capabilities needed to diagnose, treat, and safely monitor a high volume of Alzheimer's patients. Our view is that sites are progressing; as one example, we estimate that since LEQEMBI's launch began, almost one-third of customers have started diagnosing MCI and mild Alzheimer's disease patients for the very first time. Based on Medicare claims data, prescribers have on average cut the time from diagnosis to first infusion by six weeks since the start of last year; this year, we are also seeing meaningful gains in how long it takes sites to add patients after their first one and in how deeply they prescribe. Monthly PET testing is up roughly fivefold across the last year and a half. Testing with blood-based biomarkers from two of the major lab companies has risen 50% over the past six months and has almost tripled across the past year. In our view, this is an early and encouraging signal that awareness of blood-based biomarkers is high and that willingness to adopt them exists. Together with the Alzheimer's community, we will educate people about the quality of these tests and examine the chance for broad use. Because the market infrastructure has matured in this way, we felt confident earlier in the year to roll out new initiatives with Eisai, among them sharper messaging, a targeted brand campaign, and a more precise focus on the physicians most likely to prescribe; we believe these are building momentum. U.S. revenue was up 20% quarter-over-quarter in Q2, and our new LEQEMBI prescriber count has risen 34% year to date. It is especially encouraging that, in our view, the anti-amyloid market is now expanding by about 15% in Q2; given these dynamics, we are prompted to move into the next phase of initiatives meant to lift LEQEMBI prescribing further. Awareness of Alzheimer's disease is high today. Sadly, awareness among patients and caregivers about new treatments is low; even so, our research indicates that when patients ask about LEQEMBI, an HCP will prescribe it most of the time. Since health systems have improved their treatment capabilities, we launched our direct-to-consumer campaign on TV and digital platforms to drive patient demand and awareness; during our campaign testing, patients and caregivers reported feeling empowered to seek treatments and earlier intervention if LEQEMBI can help them remain like themselves for a longer time. At the same time, we intend to pilot an expanded field team later this year to learn how to enhance PCP referrals in key geographies; we are also getting ready for the potential subcutaneous formulations of LEQEMBI, which we think would bring added convenience and optionality for patients, caregivers, and HCPs. Going forward, we believe our disciplined execution, efficient investments, and our capacity to adjust to evolving market dynamics put us in position to maintain this momentum and achieve continued growth. I will now hand it over to Robin for an update on our financial results.

Robin Kramer

executive
#5

Alisha, thank you. There are a number of key things I'd like to cover regarding the strong financial results we reported for the second quarter. To be clear, all of the comparisons I'll reference are versus Q2 of 2024. Revenue for the quarter grew 7%, which speaks to strong commercial execution — particularly from the four products we have launched, which generated $252 million in revenue during the quarter — as well as our U.S. MS business. That strong commercial execution, together with disciplined management of operating expenses, drove 4% growth in non-GAAP diluted EPS for the quarter. Excluding the roughly $0.26 impact from acquired IPR&D upfront and milestone expense in the quarter, non-GAAP diluted EPS would have been $5.73, representing a 9% increase. With the business performing so well in the first half of the year, we are raising our full-year 2025 financial guidance. I'll provide the details of that guidance shortly. But first, let me review our Q2 performance. Starting with our MS franchise: in the U.S., as Alisha noted, we had a strong quarter with $657 million in revenue. Among the drivers were higher VUMERITY demand, approximately $32 million in favorable inventory dynamics <<inaudible>> and TYSABRI, along with an estimated favorable gross-to-net change impact of roughly $48 million across the franchise, $27 million of which benefited VUMERITY. Outside the U.S., sales are primarily impacted by expected generic pressure on TECFIDERA and a TYSABRI biosimilar in Europe; we continue to defend our IP, but we expect increasing competitive pressure on the ex-U.S. MS business in the second half of 2025, particularly for TECFIDERA in Europe. On SPINRAZA, we remain encouraged by the consistency of demand worldwide. As expected, ex-U.S. SPINRAZA was affected by the drawdown of the inventory build from the first quarter, and we expect that to continue into Q3; we still expect full-year 2025 global SPINRAZA revenue to be fairly comparable to 2024. Due to shipment timing, we expect second-half revenue to be lower than the first half. Each of our four launch products saw higher demand in the second quarter, and together they contributed $252 million in revenue to Biogen — up 26% quarter-over-quarter and up 91% year-over-year. During the quarter, the year-over-year performance of these products collectively offset the decline in our MS portfolio; we continued to see steady sequential demand growth for LEQEMBI globally, with global in-market sales booked by Eisai in Q2 of approximately $160 million. That number includes an approximately $35 million favorable impact from the timing of shipments to China, as the collaboration optimized global inventory positions in Q2; we expect that inventory build to be drawn down during the second half of the year. Encouragingly, excluding the China shipment timing impact, global sales increased 29% sequentially and 211% year-over-year. SKYCLARYS continued to experience demand growth worldwide. In the U.S., demand growth during the quarter more than offset the Medicare discount dynamics we had anticipated. Looking beyond the U.S., the timing of shipments in certain markets was a drag on SKYCLARYS. We expect this product to continue growing globally, and we're seeking reimbursement in selected European nations as well as Brazil. ZURZUVAE saw a sharp jump in demand during the quarter. Q2 revenue came to $46 million, as Alisha noted — up 213% from a year ago and 68% above the previous quarter. Bear in mind that Biogen receives 50% of ZURZUVAE's profit or loss, booked in the collaboration profit sharing line of our P&L. I should point out that we're aware IQVIA changed how it reports shipped prescriptions for ZURZUVAE and other products earlier this month, as part of its routine data review; this could mean a lower capture rate. Even so, we remain optimistic about ZURZUVAE's outlook, including its potential in Europe after the recent favorable CHMP opinion. Turning to contract manufacturing revenue, the growth there stemmed from manufacturing batch releases that occurred earlier than anticipated, some of which relate to LEQEMBI due to our Q4 scheduled plant maintenance. Our stance is still that contract manufacturing revenue will be roughly flat between full year 2025 and full year 2024, and we expect minimal revenue in Q4 2025 related to the planned maintenance. Now, a few comments on the other P&L items. In Q2 2025, higher contract manufacturing revenue, which carries lower margins, weighed on non-GAAP cost of sales, continuing the trend from the first quarter when we pulled batches forward ahead of that Q4 plant maintenance. Non-GAAP core operating expense — R&D plus SG&A — declined 2% versus a year earlier, reflecting ongoing execution on our R&D prioritization and fit-for-growth initiatives. Non-GAAP operating income took a hit of roughly $47 million from acquired in-process R&D charges. That amount includes $16 million from the City Therapeutics deal and a $30 million milestone related to launching the second phase III trial for salanersen. Excluding the acquired IPR&D impact, non-GAAP operating income would have been close to $1 billion, up 5% year-over-year. Now, a brief note on our balance sheet. Free cash flow in the second quarter was $134 million. That number reflects $745 million of cash tax payments made during the quarter. Our annual cash tax payments are heavily concentrated in Q2; also, during the second quarter we used proceeds from $1.75 billion of newly issued debt to fully redeem $1.75 billion of senior notes maturing in September. While this financial move left our overall debt profile unchanged, we expect roughly $15 million to $20 million of incremental interest expense in the back half of 2025, which is incorporated into our revised guidance for the year. We ended the second quarter with $2.8 billion in cash and approximately $3.5 billion of net debt. In our view, our balance sheet is in a strong position, which gives us the capacity to keep investing in growth opportunities, whether those arise internally or through external deals. We'd add that the structure of our business model may leave us comparatively better insulated from macroeconomic strain and policy-related uncertainty. At present, a substantial portion of the U.S. product revenue we generate derives from items largely manufactured within the United States. We recently outlined intentions to continue funding our North Carolina manufacturing footprint. This spans several years and covers both capital and operating costs, with the aim of upgrading those facilities and broadening what we can produce, allowing us to push Biogen's late-stage pipeline further ahead and support our upcoming set of potential products. One more thing to note: in our view, additional aspects of how the business is organized bear on our ability to remain resilient amid an unpredictable climate; a sizeable percentage of our revenue is generated beyond the U.S. We also hold a meaningful rare disease operation. Regarding payer channel mix domestically, it is varied and tilts toward commercial payers. We believe these elements count as we navigate today's conditions, and we'll continue monitoring shifts in the landscape. Separately, we expect $15 million to $20 million of incremental interest expense.

Robin Kramer

executive
#6

Moving on to our outlook, we've lifted our 2025 full-year non-GAAP diluted EPS to a range of $15.50 to $16.00, up from $14.50 to $15.50. This increase reflects a more robust anticipated business picture for the entire year, driven mainly by the solid revenue results in the first half, which include the resilient showing of the U.S. business, MS, and how our launch products have performed, though this is partly countered by the effect of the City Therapeutics transaction during the second quarter. Keep in mind that the $30 million felzartamab milestone I referenced earlier was already factored into the guidance we gave previously. Here are a few key points behind the raised guidance: we now anticipate total revenue for 2025 will be roughly flat versus full year 2024. That captures the strong first-half revenue results, including the resilient showing of the U.S. MS business. If you set aside the $75 million of favorability from inventory along with the one-time gross-to-net adjustments in the second quarter, we anticipate U.S. revenue trends in the latter half of 2025 will be about even with the first half. We also anticipate heightened competitive pressures affecting the ex-U.S. MS business during the second half of 2025, especially for TECFIDERA in Europe. As I noted earlier, we expect very little contract manufacturing revenue in Q4 of this year because of scheduled plant maintenance work. Crucially, we continue to be on track to achieve the $1 billion in gross savings and $800 million in net savings from our fit-for-growth initiative; during the second half of 2025, we intend to make further investments in R&D to support acceleration and expansion of clinical development activities, mainly to back rare disease; on this call, we discussed how excited we are about advancing salanersen into registrational studies and our plans for a fourth indication for felzartamab. As we keep growing our ever more promising pipeline, we think it's essential to make these investments to support our long-term growth goals. We now anticipate combined non-GAAP R&D and SG&A expense for the full year 2025 to come in at roughly $4 billion. Please make sure to look over this slide and our press release for additional important guidance assumptions. Lastly, we stay focused on capital deployment that delivers long-term value for our shareholders. With that, I'll hand the call back to Tim to open it up for questions.

Tim Power

executive
#7

Thanks, Robin. Cynthia, could we go to the first question, please?

Phil Nadeau

analyst
#8

Morning, and thanks for taking our question — congratulations on a strong quarter. What we want to ask about is actually the AHEAD 3 to 45 trial, which has potential for an interim in the CASSANOVA, TRAILBLAZER ALZ 3 trial coming up. There's a lot of focus on early Alzheimer's. Could you remind us whether a similar interim exists in AHEAD 345? And maybe more broadly, could you discuss the differences in design between AHEAD 345 and TRAILBLAZER ALZ 3? Thank you.

Christopher Viehbacher

executive
#9

Priya?

Priya Singhal

executive
#10

Thank you. Taking a step back, our view is that the opportunity for amyloid treatments among people who haven't yet shown symptoms is quite substantial. This matters a great deal to patients. We'd certainly want to see what data our competitor comes up with. Should their study succeed, I believe that would benefit patients and the whole amyloid category. There are some extremely meaningful and notable distinctions in the way we've tried to tackle the issues that prescribers confront when considering anti-amyloid medications for the pre-symptomatic group. The initial and biggest one concerns the scientific questions we're posing. AHEAD 345 consists of two studies: AHEAD 3, which seeks to answer whether we can stop amyloid from building up further, and AHEAD 45, which asks whether we can truly prevent cognitive decline among patients who already have more than 40 centiloids of amyloid in their brains. The next element is that we were extremely particular about how we recruited and included patients; we screened people with amyloid PET prior to enrolling them, and we required a CDR global score of zero, meaning absolutely no cognitive decline whatsoever. Our competitor, by contrast, adopted mixed inclusion criteria, which brought in telephone interviews for inclusion, and also allowed CDR global scores of 0.5 and 1, meaning mild and MCI dementia were permitted at baseline. That's a crucial point. Lastly, I'd say it comes down to the endpoints. For AHEAD 3, we're examining a biomarker endpoint, which we think will prove very important. For AHEAD 45, we're examining a sensitive, specific preclinical Alzheimer's disease composite endpoint. All in all, I think these will be very different trials. We're expecting a readout in 2028; as for the question of interim analysis, we're keeping our options open, naturally, but right now, we're planning for 2028. Thank you.

Tim Power

executive
#11

Thanks, Priya. Could we go to the next question, please, Cynthia?

Eric Schmidt

analyst
#12

Thanks. It's great to be on this call after Phil Nadeau. I've got a question about LEQEMBI as well. This might be one for Alisha. It's more about the market side. Some third-party data we've come across indicates LEQEMBI might be shedding a bit of share in the U.S. Could you speak to the competitive dynamic? Clearly, donanemab recently got a label update for safety, which could strengthen their competitive position.

Alisha Alaimo

executive
#13

Thanks for asking. Just as we expected and communicated previously, and as I said on this call, we felt a second therapy would assist in growing the market by generating greater awareness among physicians, patients, and caregivers. As I also noted, this marks the first occasion we've observed this market expand by roughly 15%, measured by total new patient starts. We consider this a highly encouraging sign. That said, regarding competitive dynamics, we're finding that donanemab encounters the same obstacles we did with health systems, which we've been working hard to resolve over the last two years. It's worth noting that we think our competitor's growth is mainly coming from HCPs already prescribing LEQEMBI or physicians collaborating with LEQEMBI prescribers at the same location. LEQEMBI continues to maintain the bulk of market share, at nearly 70%. I think when it comes to new patient starts, doctors will try new drugs that come onto the market. We're also pleased that we've seen quite robust new writer growth so far this year; moreover, 70% of that new writer growth originated from physicians at new sites of care. LEQEMBI is genuinely fueling this quarter-over-quarter expansion of new writers at new sites. Going forward, with our maintenance option and our possible sub-q options, this will deliver truly excellent optionality that clearly our competitor lacks as well. Regarding the new label update, it's genuinely too soon to tell how it will affect a physician's decision. What I can say is that, based on market research we've conducted, it shows that a number of doctors were already following this kind of schedule and dosing regimen before the label update; also, remember, HCPs still must perform the same number of MRIs, and that hasn't changed either. RA has always been a key factor, and the RA figures clearly didn't shift much in the dosing regimen. It helps that physicians gain more real-world experience, particularly with McKenzie, and we'll continue watching it closely going forward.

Priya Singhal

executive
#14

Thank you as well, Alisha — I'd like to tack on one more thing here. At AAIC, there was in fact a separate presentation delivered by Dr. Burke, work by Sabag et al., which was an indirect treatment comparison addressing the RA events for lecanemab alongside those for denanemab, drawing on the modified titration. From what I gather, that group concluded the modified titration appears largely limited to the homozygotes, and also that TRAILBLAZER 6, where this modified titration was evaluated, enrolled a notably smaller patient count. No real conclusion emerged that it differed in any very clear-cut way. That, too, strikes me as a key point to keep in mind.

Tim Power

executive
#15

Thanks, Priya. Let's go to the next question, please.

Michael Yee

analyst
#16

Hello, everyone. Thank you. Congratulations on the ongoing strong momentum; we had an inquiry regarding what's happening in the SMA marketplace. I value the work you've done with salanersen. Myostatin treatments might also arrive within 1 or 2 months, and Roche, your rival, is likewise quite optimistic about its myostatin effort to gain SMA share. Perhaps you could just share your view on how myostatin might shift the landscape, whether you see it as complementary to SMN correctors, and what effect it would have on you should rivals offer combo products? Thanks.

Alisha Alaimo

executive
#17

I'll take that question and begin the response. The myostatin mechanism is something we've been examining for a good while now, and our belief is that it will provide solid added value to patients. We don't view it as a primary rival to SPINRAZA or to the SMA treatments presently in use; in our view, that won't pose a problem for us.

Tim Power

executive
#18

Great. Let's go to the next question, please, Cynthia.

David Amsellem

analyst
#19

Thank you. I'd like to raise an issue regarding the lupus pipeline. To start with daprolizumab, could you perhaps tell us the soonest point at which we might get results from that second phase III? And on a wider note, your strategy for developing lupus drugs involves multiple mechanisms. I was hoping to get your thoughts on how the competition looks. There are oral therapies out there, for example SOTYKTU, that are in late-stage development in this area, right? Of course, we need to find out how the data turn out. In a landscape that's becoming more crowded and might soon include oral options, how do you view daprolizumab and lutophilimab? Thanks.

Priya Singhal

executive
#20

Thanks, David. Broadly speaking, the initial point I want to raise is that our approach to lupus has genuinely centered on the unmet need. Once you examine that unmet need, it becomes clear pretty fast that in spite of a highly competitive field of investigational drugs, daprolizumab was in fact just the third agent ever to record a positive phase III trial. That reveals a good deal about the heterogeneity, the variability across the patient population, and the unmet need that remains. The next aspect is that we've tried to address this through a very wide, holistic lens. What I mean by that is mechanism of action. Through lutophilimab, our aim is really to address the type- 1 interferon signature. We're targeting the BDCA-2. In phase II, we have proof of concept from our part A and part B, covering both cutaneous and systemic lupus. Through daprolizumab, we're examining a far broader angle — the CD40 ligand, CD40 pathway, which has an effect on both T and B cells. What we produced from our initial phase III gives us confidence that we can target the disease effectively, since we demonstrated the impact on BICLA. Crucially, beyond BICLA, we demonstrated how important daprolizumab is for the moderate to severe patient population and for lowering flares — cutting severe flares by 50% — as well as for sparing steroids. Today I presented, naturally, the fatigue data that we'd also shared earlier in the year at EULAR. We believe this is a highly important area of unmet need, and we're addressing it scientifically by examining various phenotypes. In our view, these will complement one another. I should add that we're also trying felzartamab, an anti-CD38, currently in phase 1, yet we stay enthusiastic about that mechanism of action for lupus nephritis. We keep exploring various angles. As for your question on when results might arrive, I believe we're looking at the 2027 to 2028 timeframe for the second phase III; for lutophilimab SLE data, we're expecting it as soon as late next year.

Christopher Viehbacher

executive
#21

Michael, as you might have noticed from the press release, we've scheduled a seminar for an in-depth look at lupus, similar to the one we recently held for felzartamab during the last quarter. That concept of heterogeneity strikes me as really critical. We assembled a panel of four patients who spoke with our senior executives. Something I recall quite vividly from that session is one patient telling another, "Your lupus is not my lupus." That, I believe, is precisely what has made drug development in this area so challenging. An advantage Biogen holds is our background in MS. Oral therapies will certainly exist, but if you examine the MS market, Alisha, what share did the orals account for in the overall MS market?

Alisha Alaimo

executive
#22

One out of three.

Christopher Viehbacher

executive
#23

Roughly 33%. I wouldn't simply assume that in this particular market an oral product will always defeat an injectable one; what matters, in my view, is efficacy. Symptoms differ too. Fatigue has been reported by some patients, plus there are flares, joint pain. Skin problems also appear. This disease is complicated. Like I mentioned, come September we should get the chance to explore this in greater depth, and everyone is invited to that seminar.

Tim Power

executive
#24

Thanks, Chris. Let's go to the next question, please.

Umer Raffat

analyst
#25

Hello, everyone. I'd like to spend a moment addressing your dedication over the long haul to Alzheimer's, along with where things stand with Eisai. Part of why I ask is that it appears Biogen has started an arbitration concerning how commercialization is split in Europe and whether that split is fair. I'm simply wondering how things are going with Eisai and where the points of friction might be.

Christopher Viehbacher

executive
#26

To begin, we remain highly dedicated to Alzheimer's, and that's been true for a long time. In fact, I believe our alliance with Eisai stretches back a minimum of 10 years. Clearly, the money we've put into BIIB080 matters enormously for this company's future; we're still carrying out research across other modalities as well. Biogen has a track record of many partnerships and collaborations; getting companies to cooperate isn't always simple. That's just natural, since many things are rarely clear-cut in how we handle them. I'd say the Eisai relationship is stronger now than at any previous point. When I consider how much executive time at Biogen we devote to various committees alongside our Eisai colleagues, I believe the connection Alisha and her team share with their opposite numbers is incredibly solid. Our Head of Manufacturing recently held a one-on-one meeting with Eisai's CEO in Japan, and that took place after the arbitration had been filed. On the development front, I'd say the working relationship is quite close. There will be occasions when disagreement arises. I think that's the case regarding how we launch in Europe. We're simply adhering to the process laid out in our contract. My expectation is that it will go to arbitration. I don't believe there's anything unusual about it. Such things happen in relationships, yet it hasn't harmed the broader working relationship with Eisai.

Tim Power

executive
#27

Let's go to our next question, please.

Brian Abrams

analyst
#28

Morning, everyone. I appreciate you fielding my question, and congratulations on the results this quarter. It appears that blood-based biomarker utilization is growing quite substantially. Could you elaborate a bit further on the way you provide education regarding correct patient triage when using these novel diagnostics, and based on your firsthand experience in the field, what do you believe will be required to persuade neurologists that these tests are viable substitutes for PET or CSF? Might that occur in the near term, and what kind of inflection point in beta-amyloid uptake could follow? Thank you.

Christopher Viehbacher

executive
#29

Yes. Alisha, I believe you can speak to the fact that you are observing a tremendous amount of activity in this area within the market. Could you possibly offer some additional color commentary on that?

Alisha Alaimo

executive
#30

Yes. Thanks for asking that. Right now, Alzheimer's blood tests are advancing incredibly quickly. Actually, that pace is far beyond our expectations for where things would stand at this point. We genuinely see this as a crucial juncture, particularly for patient diagnosis. During my opening comments, I noted that testing almost tripled over the last 12 months. Only this week, the Alzheimer's Association released its inaugural practice guidelines covering blood-based biomarkers. As you likely know well, these tests offer greater convenience, speed, and lower cost than the current options, CSF or PET. Market dynamics remain in flux, yet I can tell you what we know as of today, and I'm certain it will shift again by our next earnings call. Above all, our market research indicates that neurologists have very high awareness, and a large number already use these tests. If someone is already prescribing an anti-amyloid therapy, that person also shows a stronger tendency to order these tests and administer them to patients. Claims data shows PCPs are adopting them too. Still, we think these early adopters apply them to only a small share of their patients. They aren't used every time in the offices, but they are used for a portion. Although utilization is rising substantially, physicians mainly rely on them for triage. That means if the result comes back negative, the physician rules out Alzheimer's. Yet even when a result is positive or indeterminate, we think most physicians continue confirming with CSF and PET scans at present. The larger opportunity, the bigger one awaiting us, is making these tests the standard for amyloid confirmation; to achieve that transition, we are actively working to build awareness and education, and we require real-world evidence for physicians. More specifically, we think education about the new guidelines is necessary. Those have only just been released. We will certainly need to get that information out there. Several tests meet the 90% sensitivity and specificity threshold included in the guidelines; we also think physicians need clarity on whether these tests suffice for therapy reimbursement. By therapy reimbursement, I mean specifically around CSF. That is since PET, or pardon me, with CMS. The reason is that only PET and CSF are chiefly used today. Physicians won't find out until they attempt to enter that into their CMS database. Since not many are doing that right now rather than CSF or PET, we don't know if reimbursement will come through. We will pursue clarity alongside the payers and the physicians and ensure they have it; this is evolving fast, but there is considerable potential to speed up diagnosis for patients. What we're seeing in the market today leaves us quite encouraged. What we're seeing is that testing volumes are speeding up to a degree that outpaces even the forecasts we had for the period through the close of the year.

Tim Power

executive
#31

Great. Thanks, Alisha. Can we go to the next question, please, Cynthia?

Jay Olson

analyst
#32

Hey there. Nice work on the quarter, and I appreciate the update. We’d like to ask about SubQ LEQEMBI. You shared some significant data updates regarding LEQEMBI at AAIC. Like Alisha said before, SubQ appears to be a major point of difference versus Donanemab. Could you discuss any physician feedback you received at AAIC? How big is the additional patient group you’re able to reach with SubQ? Is there a chance for direct-to-consumer education regarding SubQ LEQEMBI? Thanks.

Christopher Viehbacher

executive
#33

Priya, would you like to begin with AAIC, and then I’ll follow?

Priya Singhal

executive
#34

Yes, I'll go ahead and kick things off. Thank you, Jay. On the whole, we're quite enthusiastic, since, as we noted when 2025 began, our view was that blood-based biomarkers would serve as a significant catalyst. As I think you just heard from Alisha, that effort is continuing. The other key item was the intravenous maintenance approval we secured for LEQEMBI. At this point, we're just weeks away from the PDUFA date for subcutaneous maintenance. Our view is that, should approval come through, this would represent a truly significant step forward for the field, since it brings added convenience and optionality, takes away certain obstacles to treatment, and makes the infrastructure more efficient. What we're aiming for with subcutaneous autoinjector maintenance is essentially to offer patients the choice of moving to weekly at-home injections once they finish the intravenous LEQEMBI initiation period. In addition, we're preparing to submit for subcutaneous initiation LEQEMBI therapy. Just yesterday at AAIC, we presented bioequivalence data. All in all, we're very enthusiastic about what this could bring. Yes, it sets us apart, and it also carries a safety benefit, because what we observe is not a particularly large difference and a substantially lower count of infusion reactions with subcutaneous compared to intravenous. We see this as a considerable plus, with safety and efficacy appearing quite comparable; with that said, I'll hand things over to Alisha. Before doing so, I should note that we've run many ad boards and spoken with numerous key opinion leaders, and enthusiasm for subcutaneous is high. I'll now turn to Alisha for further specifics on that.

Alisha Alaimo

executive
#35

Thanks, Priya. Just like in any other market, doctors and patients appreciate having choices, and they appreciate having flexibility. Whenever we launch something that delivers both of those, excitement builds in the market. That said, I realize this question concerns SubQ, but the community has also responded very warmly to IV maintenance. Although patients are only now reaching their 18-month marks, feedback is coming in that patients are rolling off. They are transitioning to the IV maintenance. Honestly, it provides them with, once again, greater optionality and flexibility, since they don't have to come in twice a month, and that has already been a positive. Now we're introducing SubQ. Physicians have told us in market research and in conversations we've had that they will, should we secure the potential approval of this happening for either initiation or maintenance, present all the options to patients, and they will let the patient decide what suits them best. We do have many patients living in rural areas, and we're hearing that those in rural areas will probably want to go on SubQ, and they will choose to go on SubQ. Yet we also have patients on IV who enjoy coming into the infusion centers; it really will come down to patient choice and what's going to be good for their lifestyle. I will say that physicians love the fact that they are going to have so many different options when it comes to LEQEMBI.

Tim Power

executive
#36

Let's go to our next question, please, Cynthia.

Salveen Richter

analyst
#37

Thank you, and good morning. To pick up on what was said earlier regarding business development, how big a lever is that for you at this point, given that you have a steady cadence of pipeline catalysts as you head toward the end of the year and past it? With that in mind, are you targeting earlier-stage assets, and given the interest in building out that vertical, is I&I the primary area of focus? Thank you.

Christopher Viehbacher

executive
#38

Yes. Thanks, Salveen. I'd say early-stage is certainly something we're considering, since I believe our late-stage pipeline is genuinely quite strong. In my view. One observation from my lengthy career is that we, especially those of us at senior management levels, haven't devoted sufficient attention to research. That is truly the place where you can acquire assets at a very attractive cost. You're able to leverage certain strengths of a bigger company to genuinely mold those molecules into medicines. Our research organization has undergone a full overhaul, and we've cut head count substantially — though the intent wasn't to spend less, but rather to spend in a different way. We're going to pursue far more deals along the lines of City Therapeutics. Actually, I'd even point to Human Immunology Biosciences, where we managed to keep the whole organization intact and discovered a cultural approach inside Biogen such that big-company capabilities — procurement, for instance, and the ability to run clinical trials globally — can support an entrepreneurial, nimble group like HI-Bio. That's our aim at the early stage, and it's really about ensuring we aren't stuck in another period with a pipeline gap 10 years down the road; that being said, we continue to evaluate other assets as well. How interested you are in late-stage M&A moves inversely to how confident you feel about the pipeline. That's partly about confidence, but you're also worried about distraction. I believe we're breaking new ground in a number of areas. We're assembling a massive team focused on lupus and exploring nephrology, essentially pre-launching these programs. When we evaluate opportunities — and I've always maintained you can never have too much pipeline — it has to be a strategic fit with what we're already doing. We don't want to overextend our teams beyond what's necessary, and it has to make financial sense. Some assets are available out there. Not everyone agrees they're appropriately valued, which sometimes makes getting deals done difficult. Certain things are overvalued. We're looking. I'd say our confidence in Biogen's future keeps growing. I think we've got the company truly firing on all cylinders. It's performing well. Should we find something we genuinely believe will add shareholder value, we'll do it. If not, I think we're really concentrated on the entire spectrum of the development chain.

Tim Power

executive
#39

Thanks, Chris. Let's go to the next one, please.

Julian Pino

analyst
#40

Hi everyone. Julian here, filling in for Paul. We really appreciate you addressing our question. So, to be more precise, once more, building on the subcutaneous LEQEMBI topic. I believe folks are genuinely attempting to gain a clearer picture of the practical steps involved in getting a subcutaneous start going once that finally becomes available. Do you expect that at first this will mostly be given at centers, and afterward patients will gradually transition to receiving the drug at home? I'm simply wondering how you anticipate this unfolding and what kind of benefit this will eventually deliver, especially considering the worries about ARIA with this category of treatments? Thank you.

Priya Singhal

executive
#41

I'll begin, Julian. It's Priya here. Broadly speaking, the manner in which we ran the trials and the manner in which we produced the data means we truly possess flexibility for this to be self-administered by the patient, the caregiver, medical staff, or the physician. That flexibility is something we keep. As for precisely how we are highlighting and forecasting that it would be utilized, I'm going to hand things over to Alisha. Prior to that, we mentioned during AAIC that we shared findings from our human factors study. Those were quite positive. I'd urge all of you to review that, since it demonstrates that in fact patients who received training managed to accomplish this independently, and the autoinjector is relatively straightforward to operate. That data was highly positive and thrilling. I'll pass it to Alisha to discuss the real logistics in greater detail.

Alisha Alaimo

executive
#42

Appreciate that, Priya. Once SubQ becomes available, our view is this represents a terrific opening — for the people receiving treatment, for the doctors treating them, and above all for those physicians doing a high volume of writing, of whom we now have quite a few. It lets those doctors avoid tying up a chair on someone who may require it, particularly when that person chooses to move to IV. Regarding SubQ, in our conversations with physicians and in the market research we review, the findings indicate everything hinges on each individual's circumstances — whether a caregiver is present, and whether the doctor in question considers themselves highly capable when it comes to handling ARIA, clearly. Certain physicians right now sit earlier in their LEQEMBI prescribing journey, and those doctors continue to prefer being hands-on, wanting to see the person and bring them into the clinic. Others, who look after hundreds of patients, are entirely at ease putting someone on SubQ from the start. My honest sense is it all boils down to that discussion and whoever happens to be seated across from the physician — does that individual wish to self-administer, do they have someone caring for them. We're additionally exploring whether support could be provided for injections in the home, sparing them a trip to the office. The choice for them to visit the office remains available as well. This is going to be a case where they genuinely enjoy considerable latitude in making that call, shaped by whatever that person requires at that particular moment.

Tim Power

executive
#43

Thanks, Alisha. Let's go to our last question, please, Cynthia.

Christopher Viehbacher

executive
#44

Regarding the addressable market, I believe we mentioned during the thematic seminar that roughly 11,000 patients come forward each year. Using the typical IgAN price as a rough sense of potential value, that figure sits at approximately $150,000. When you consider the addressable market overall, the total likely lands somewhere near $1.5 billion. That represents a meaningful opportunity on its own, and our genuine belief is that felzartamab will hold the strongest position. We are running every one of the studies needed for this. What we have here is precision immunology; our view remains that we will reach the market first, and that we can capitalize on it fully, extracting the greatest benefit from that market.

Priya Singhal

executive
#45

One more thing to mention, and thank you, Chris. I want to note as well that we shared today that we will also be looking into the felzartamab opportunity in late microvascular inflammation. That matters since late microvascular inflammation is in fact a newly classified phenotype of kidney transplant rejection. It has only recently been added to the BRAMP classification, as it was classified before. These patients had been classified as no AMR, given that they lacked donor-specific antibodies, which carries a very high risk of graft failure; now, in this case, we're considering how felzartamab works, targeting the CD38-positive natural killer cells, which we believe matter greatly for the disease and pathology. There is a scientific rationale here. This on its own also involves roughly 5,000 to 6,000 patients. We believe it will augment the potential opportunity in AMR.

Tim Power

executive
#46

Alright, thank you, Priya. That’s all the time we’ve got for today. We appreciate everyone joining. Should you have any questions and would like to follow up, please get in touch with the IRT. Thanks.

Operator

operator
#47

This concludes today's call. Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.